CTOs on the Move

St Charles Parish Hospital

www.stch.net

 
St Charles Parish Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Luling, LA. To find more information about St Charles Parish Hospital, please visit www.stch.net
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.stch.net
  • 1057 Paul Maillard Rd
    Luling, LA USA 70070-4349
  • Phone: 985.785.3662

Executives

Name Title Contact Details

Similar Companies

Lavie Administrative Services

Lavie Administrative Services is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chicago Hospital Risk Pooling Program

Chicago Hospital Risk Pooling Program is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedMinder Systems

MedMinder Systems Inc. provides services that simplify medication management and improve medication adherence. We offer an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages & phone calls.

Avoca Christian Church

Avoca Christian Church is a Bristol, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.